Director/PDMR Shareholding

RNS Number : 4684R

Dechra Pharmaceuticals PLC

11 September 2014

 



11 September 2014

Dechra^® Pharmaceuticals PLC

(Dechra or the Company)

Director shareholding

Exercise of option:

Dechra Pharmaceuticals PLC announces that on 11 September 2014, Anne-Francoise Nesmes, Chief Financial Officer, exercised a nil cost option over ordinary shares of 1p each in the Company. The option was granted to her on 27 September 2013 as part of the recruitment award referred to in the Company's Directors' Remuneration Report for the year ended 30 June 2014.

Anne-Francoise Nesmes sold sufficient shares (acquired pursuant to the exercise) on 11 September 2014 in order to fund the resulting tax liability. 

Options Exercised	Shares Sold	Sale Price per share	Total beneficial shareholding following this announcement	Percentage of issued share capital
41,739	19,677	£7.6017	22,062	0.025%

The exercise of the option was subject to a performance review, as a result of which the vesting percentage is 100%.

For further information, please contact:

Zoe Goulding, Company Secretary and Solicitor                 

Telephone number: 01606 814730

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

END

 

 

RDSQKDDKPBKDPCD